Navigation Links
Jefferson awarded multi-million dollar grant from National Eye Institute for new clinical trial
Date:10/1/2008

PHILADELPHIA Researchers at the Farber Institute for Neurosciences at Thomas Jefferson University and the Department of Psychiatry and Human Behavior at Jefferson Medical College of Thomas Jefferson University were recently awarded a $3.7 million grant from The National Eye Institute to study depression in patients diagnosed with age-related macular degeneration (AMD). Barry W. Rovner, M.D., director of Clinical Alzheimer's Disease Research at the Farber Institute for Neurosciences and professor of Psychiatry and Neurology at Jefferson Medical College; and Robin Casten, Ph.D., associate professor of Psychiatry and Human Behavior at Jefferson Medical College, will lead the single site study of 200 AMD patients, who will be followed for 12 months, to determine the effectiveness of a treatment program designed to prevent depression and disability in these patients.

AMD is the leading cause of vision loss in Americans 60 years of age and older. It gradually destroys sharp, central vision, which is needed for seeing objects clearly and for common daily tasks such as reading and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. In some cases, the disease advances so slowly that people notice little change in their vision. In others, it progresses faster and may lead to a loss of vision in both eyes.

"Vision loss in the elderly is a major risk factor for depression. The disease robs older persons of their ability to perform everyday activities and limits their independence," said Dr. Rovner. "The loss of these abilities and having to give up valued activities can lead to depression. We want to find ways to improve the vision skills of people with AMD and thereby prevent depression."

The Low Vision Depression Prevention Trial will test a combined treatment to prevent depression and disability associated with AMD. It will test the efficacy of a low vision rehabilitation and psychological intervention program designed to treat/prevent depression in patients diagnosed with the disease by helping them maintain their independence and participation in enjoyable activities. The study consists of two low vision optometry visits, in which specially trained optometrists will evaluate visual function and develop a rehabilitative plan; and six in-home occupational therapy visits where low-vision occupational therapists will teach compensatory strategies to improve visual ability and administer a behavioral treatment to activate subjects and enable them to remain engaged in valued activities.

"Vision loss in the elderly is extremely distressing, significantly impacts quality of life, and is a risk factor for nursing home placement," said Dr. Casten. "Finding ways to help these patients maintain their independence and engagement with life is key to promoting successful aging."


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University to Host Summit With National Experts to Discuss A New Age in Dementia Care
2. Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis
3. East Jefferson General Hospital Selects Allscripts Electronic Health Record, Offers Free Electronic Prescribing for Affiliated New Orleans-Area Physicians
4. Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show
5. Blocking signaling protein prevents prostate cancer spread, Jefferson scientists find
6. Jefferson, Ohio State team find gene signature profile for metastasis
7. Monitoring blood flow helps improve prostate biopsies, Jefferson researchers report
8. Traditional herbal medicine kills pancreatic cancer cells, Jefferson researchers report
9. Independence Blue Cross, Jefferson Health System Reach Agreement on New Three-Year Contracts
10. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
11. Jefferson scientists discovery may help explain smoking-pancreatic cancer link
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer and manufacturer ... barn kits, which can be found on its website at SouthlandLogHomes.com. , The designs ... and they highlight the craftsmanship of timber post and beam construction. The result ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... W.S. ... products, announced today that it has been recognized as one of the best small ... Badger was named as one of nine small businesses providing progressive benefits to new ...
(Date:5/27/2016)... ... 27, 2016 , ... With over 60 percent of acute stroke survivors being ... product to aid in the rehabilitation process has steadily increased. Ekso Bionics had been ... hemiplegia due to stroke. , Ekso Bionics has now received clearance from the U.S. ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign ... inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also provides ... associations and industry leaders such as Bioness. , As patients feel increasingly ...
(Date:5/27/2016)... ... 2016 , ... Beleza Medspa has initiated a new program to ... the first time that Coolsculpting is being used for for more than just cosmetic ... they meet the prescribed body-fat standard, measured by the circumference-based tape method. The ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 2016  A new study highlights the necessity of health literacy within the technology ... American College of Radiology , a majority of oncology patients undergo imaging screenings without ... http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... May 27, 2016 ... company focused on late-stage drug development, today announced ... of pivotal batches required for registration of ... (FDA). This follows Kitov,s announcement in ... successfully met its primary efficacy endpoint. ...
Breaking Medicine Technology: